SUBSCRIBE
SUBSCRIBE

A2 Biotherapeutics

NEWS
Pictured: Shell game with business executives
Business
C-Suite Shuffle: A2 Bio, Bayer, BioNTech and More
See our latest overview of people coming and going from executive positions at biopharma companies covered by BioSpace.
March 26, 2024
 · 
4 min read
 · 
Neil Versel
Business
Belldegrun’s Third Fund Continues “Bold Investment Strategy” with $825 Million
Vida Ventures III will approach investments the same way its first two funds do, identifying and investing in what they believe to be transformative biomedical innovative companies.
June 24, 2021
 · 
3 min read
 · 
Mark Terry
AWARDS
  • 2024 Best Places to Work
JOBS
IN THE PRESS
BioMidwest
A2 Bio Highlights Progress of CAR T-Cell Clinical Programs in Three Poster Presentations during the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
May 29, 2024
 · 
6 min read
Drug Development
A2 Bio Announces First Patient Dosed in EVEREST-2 Phase 1 Clinical Trial of Novel Mesothelin Logic-Gated CAR T
May 16, 2024
 · 
3 min read
Biotech Beach
A2 Bio to Highlight Progress of CAR T Clinical Programs in Three Poster Presentations at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
April 24, 2024
 · 
3 min read
Business
A2 Bio Appoints James Robinson as New Chief Executive Officer and Member of the Board of Directors
March 25, 2024
 · 
3 min read
FDA
A2 Bio Receives FDA Orphan Drug Designation for Novel Cell Therapy Program A2B530 in Colorectal Cancer
March 4, 2024
 · 
2 min read
Biotech Beach
A2 Bio Presents Oral and Poster Presentations Highlighting BASECAMP-1 and EVEREST-1 Patient Screening at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 2, 2023
 · 
5 min read
Drug Development
A2 Bio Announces First Patient Dosed in Phase 1 Clinical Trial of A2B530, a Novel Cell Therapy for the Treatment of Colorectal, Pancreatic and Non-small Cell Lung Cancers
May 30, 2023
 · 
3 min read
Biotech Beach
A2 Bio Identifying Solid Tumor Patients for Possible Inclusion in Phase 1 Studies Targeting CEA and Mesothelin Expected to Begin in 2023: Update at SITC 2022
November 7, 2022
 · 
4 min read
Drug Development
A2 Bio publishes key preclinical findings demonstrating potential of its highly selective Tmod™ cell therapy platform to revolutionize the treatment of solid tumors in select patients
March 2, 2022
 · 
3 min read
Biotech Beach
A2 Bio to Present at ASCO-GI 2022 on Use of Next Generation Sequencing (NGS) to Identify GI Cancer Patients for Future Tmod™ CAR T Therapy
January 18, 2022
 · 
4 min read
Load More